Pyxis Oncology (NASDAQ:PYXS) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a note issued to investors on Monday. The brokerage set a “buy” rating and a $9.00 price target on the stock. Stifel Nicolaus’ price objective points to a potential upside of 126.47% from the stock’s previous close.

A number of other analysts also recently issued reports on PYXS. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a report on Wednesday, October 8th. Guggenheim began coverage on Pyxis Oncology in a report on Wednesday, September 3rd. They issued a “buy” rating and a $5.00 price target for the company. Zacks Research upgraded Pyxis Oncology from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 13th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Finally, Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Pyxis Oncology Stock Up 11.6%

Shares of NASDAQ:PYXS traded up $0.41 during trading on Monday, hitting $3.97. The stock had a trading volume of 1,215,319 shares, compared to its average volume of 608,932. Pyxis Oncology has a 12-month low of $0.83 and a 12-month high of $5.39. The stock has a market capitalization of $246.47 million, a price-to-earnings ratio of -2.46 and a beta of 1.40. The stock has a 50-day simple moving average of $2.47 and a two-hundred day simple moving average of $1.62.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. As a group, sell-side analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its stake in Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after acquiring an additional 9,062 shares in the last quarter. Pier 88 Investment Partners LLC grew its position in shares of Pyxis Oncology by 296.6% in the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock valued at $383,000 after purchasing an additional 292,370 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Pyxis Oncology in the first quarter valued at approximately $125,000. 683 Capital Management LLC lifted its position in Pyxis Oncology by 32.5% during the first quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock worth $539,000 after buying an additional 135,000 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Pyxis Oncology during the first quarter worth $81,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.